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James TF Lai1, John DC Dereix1, Ravi P Ganepola1, Peter G Nightingale2, Kiera A Markey4, Paul N Aveyard3
and Alexandra J Sinclair4*Abstract
Background: Medication-overuse headache (MOH) is caused by the regular use of medications to treat headache.
There has been a lack of research into awareness of MOH. We distributed an electronic survey to undergraduate
students and their contacts via social networking sites. Analgesic use, awareness of MOH, perceived change in
behaviour following educational intervention about the risks of MOH and preferred terminology for MOH was
evaluated.
Findings: 485 respondents completed the questionnaire (41% having received healthcare training). 77% were
unaware of the possibility of MOH resulting from regular analgesic use for headache. Following education about
MOH, 80% stated they would reduce analgesic consumption or seek medical advice. 83% indicated that over the
counter analgesia should carry a warning of MOH. The preferred terminology for MOH was painkiller-induced
headache.
Conclusions: This study highlights the lack of awareness of MOH. Improved education about MOH and informative
packaging of analgesics, highlighting the risks in preferred lay terminology (i.e. painkiller-induced headache), may
reduce this iatrogenic morbidity and warrants further evaluation.
Keywords: Medication-overuse headache; Analgesia; Headache; Prevention; EducationBackground
Medication-overuse headache (MOH) is a form of chronic
daily headache. Its diagnosis is based on the patients his-
tory of headache present on 15 or more days per month
with use of regular acute and/or symptomatic headache
treatment for at least 3 months [1,2]. The definition of
overuse varies depending on the medication involved and
is defined in terms of both duration of use and the num-
ber of treatment days per month [1]. MOH can be a
chronically disabling condition and may have a greater im-
pact on daily function than episodic migraine [3]. Previous
studies have demonstrated a worldwide prevalence of
MOH ranging from 0.9% to 1.8% [4-8]. Recognition of
MOH is key to improving headache disability and respon-
siveness to headache prophylactic drugs [9]. Hagen et al.
identified risk factors for MOH in which a headache* Correspondence: a.b.sinclair@bham.ac.uk
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in any medium, provided the original work is pfrequency of 7–14 days per month was strongly associated
[10]. All acute medications used to treat headache are cap-
able of causing MOH. Triptans are the most frequently
used drug by patients who develop MOH [11]. The mech-
anisms underlying MOH are unknown. However, the
number of analgesic free days, rather than the absolute
amount of medication used, is felt to be key in the devel-
opment of MOH [2,11]. There has been no previous re-
search looking at the awareness of MOH or the potential
of educational preventative strategies in MOH. Our study
aimed to investigate the awareness of MOH amongst a
network of social media users derived from undergradu-
ate students. Their self-predicted behaviour modifica-
tions following education about MOH and opinions
towards warning labels on analgesic packaging was eval-
uated. Finally, they identified their preferred termin-
ology for MOH.
Methods
This project did not involve NHS patients or staff. It was
reviewed by the University of Birmingham and permissionpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Table 1 Demographics of questionnaire responders
Study
population








Male 179 (37) 48 (24)*** 131 (46)***
Female 305 (63) 149 (76)*** 156 (54)***
Age (median; range) 23 (12–99) 22 (18–99)*** 29 (12–88)***
UK national 466 (96) 192 (97) 274 (95)
Ethnicity
White 396 (82) 160 (81) 236 (82)
Asian 48 (10) 25 (13) 23 (8)
Black 10 (2) 4 (2) 6 (2)
Mixed 9 (2) 4 (2) 5 (2)
Chinese 20 (4) 4 (2) 16 (6)
No response 2 (0) 0 2 (1)
Education level
Secondary 477 (98) 197 (100) 280 (97)
Further 443 (91) 191 (97) 252 (88)
Higher 320 (66) 133 (68) 187 (65)
Figures are expressed as means and percentages unless stated otherwise.
***indicates significant difference between healthcare training and
non-healthcare training groups at a level of P < 0.001.
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student population and their social media connections.
Undergraduate students at the University of Birmingham,
UK were approached by email or via social networking sites
and invited to complete an online questionnaire. They were
further requested to disseminate the questionnaire to their
social media network, consequently it was not possible to
quantify uptake rates. Questions were worded for a lay
audience and answers were self reported by the participant
from a selection of drop-down boxes (see Additional file 1:
Table S1). All completed questionnaires were included for
analysis. Participants’ demographics, education and previ-
ous healthcare training were recorded. Healthcare training
was self reported and included medical and healthcare
professionals and trainees. Education level was defined by
the highest qualification received at secondary (GCSEs or
equivalent), further (A levels or equivalent) or higher (dip-
loma, degree, masters) education. The type of analgesia
used and the reason for its use was documented along with
awareness of side effects (from a choice of well described as
well as irrelevant options). Participants were then asked to
select the type of pain they were treating. Those who re-
ported treating headache were subsequently asked about
frequency of analgesic use and number of headache days
over the previous month to ascertain those with MOH.
All responders were educated about the possibility of
developing MOH as a consequence of regular analgesic
use. We asked participants if and how this would alter
their behaviour (stop or reduce their use of analgesics, or
seek medical advice). Participants were then asked to se-
lect their preferred label for MOH (see Additional file 1:
Table S1). Finally, we asked respondents whether they
thought painkiller packaging should carry a warning mes-
sage cautioning users of the risk of MOH. Statistical ana-
lysis was performed with PASW Statistics for Windows
version 18.0 (SPSS Inc., Chicago, Illinois). Data were sum-
marised using counts and percentages for categorical data
or medians and ranges for continuous data. Comparisons
of two groups were made using Fisher’s exact test or the
Mann–Whitney test. The level of significance was set at
P < 0.05. A binary logistic regression analysis was per-
formed with MOH awareness as the dependent variable
and age, gender and healthcare training as the explana-
tory variables.
Findings
485 people completed the questionnaire. Responders
were divided into those that had received healthcare
education and those who had not. Participant demo-
graphics are shown in Table 1. Paracetamol was the
most commonly used analgesic (379 individuals; 78%)
(Additional file 2: Figure 1). Apart from the use of
aspirin, which was significantly lower in the healthcare
educated group (P = 0.032), our data demonstrate nosignificant differences in types of medication used be-
tween our groups.
Awareness of MOH as a side effect of regular analgesic
use was noted in just 113 (23%) individuals, 74 (38%) in
the healthcare educated group and 39 (14%) in the non-
healthcare educated group (p < 0.001, Figure 1A).The
difference between the groups was significant (p < 0.001)
in a multivariable analysis adjusting for age (p = 0.56)
and gender (p = 0.82). As would be expected, the identifi-
cation of potential drug side effects differed significantly
between the healthcare and non-healthcare educated
groups, with the healthcare group identifying the cor-
rect side-effects more frequently.
Analysis of the whole cohort revealed that analgesic
use was predominantly for headaches (395 individuals;
85%). This consisted of individuals using medication for
isolated headache (127; 27%) and for headache in con-
junction with other pain (268; 58%) (Figure 1B). 35 (7%)
had greater than 14 headache days per month and 11 (2%)
have MOH. Of those using analgesia for headaches, most
used analgesia 1–3 days per week (94; 24%), while 12 (3%)
used analgesia 4–6 days per week and 4 (1%) on a daily
basis. The majority (336; 85%) had not sought medical ad-
vice for their headache. Interestingly, evaluation of the
preferred nomenclature for MOH revealed that healthcare
educated individuals favoured the term painkiller overuse
headache (53; 27%). However, non-healthcare educated re-
spondents preferred the term painkiller-induced headache
Figure 1 Awareness, reason for using analgesia and preferred nomenclature for medication overuse headache. A) Awareness of MOH
within our sample. B) Reason for analgesic use. C) Preferred name for medication overuse headache. Respondents consisted of healthcare
educated (n = 197; grey bars) and non-healthcare educated (n = 288; white bars) individuals. Data are demonstrated as percentage of sample
selected with the absolute value below each bar. **indicates p < 0.01 and ***indicates p < 0.001.
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The current term of MOH was favoured by only 47 indi-
viduals (10%; Figure 1C).
Following education about the risk of MOH, the
majority (364; 80%) of participants indicated they would
alter their analgesic taking behaviour. Of these, 207
(57%) would reduce their usage, 69 (19%) would stop
using their analgesia and 88 (24%) would consult a doc-
tor for advice on headache treatment (see Figure 2A).
Healthcare educated individuals were significantly more
likely to suggest that they would not alter their analgesic
use (healthcare education 51 (27%) vs. non-healthcare
educated 42 (16%); P = 0.005). Figure 2B demonstrates
that the majority of our sample (397; 83%) would advo-
cate a written warning on the packaging of analgesics
explaining the risk of MOH. There was a greater propor-
tion of healthcare educated responders amongst thoseindicating their opposition to a warning label about MOH
(healthcare educated 46 (23%) vs. non-healthcare educated
group 34 (12%); P = 0.002).
Discussion
There have been no previous studies looking at the aware-
ness of MOH and this was an area requiring further inves-
tigation. Our study population consisted of individuals
with and without healthcare training and, as all participants
were identified from the social media network of University
of Birmingham students, there is likely to be significant re-
sponder bias towards a higher educated population. We
would predict, therefore, that the results in the general
population would highlight even less education and know-
ledge of MOH.
Our results highlight that participants had limited know-
ledge of MOH. The majority of our population would
Figure 2 Behavioural changes and warning label preferences following education about medication overuse headache. A) Change in
behaviour indicated following education about medication overuse headache. B) Preference for a warning label about medication overuse
headache to be added to packaging. Healthcare educated (n = 197; grey bars) and non-healthcare educated (n = 288; white bars) individuals.
Data are demonstrated as percentage of sample selected with the absolute value below each bar. **indicates p < 0.01.
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MOH and supported the idea of a warning label on pack-
aging. Our results suggest that warning labels on packaging
may have a considerable impact on the prevention of
MOH. Work by Grand et al. supports this theory, their
study involved delivering brief intervention in the form of
short, verbal information and a neurological examination
to patients with chronic headache. Both chronic headache
and medication overuse were reduced following their inter-
vention [12]. The most popular name for MOH was “pain-
killer-induced headache” and future literature aimed at
educating the public may be better understood if worded
in these terms.
Our study was the first to investigate awareness of
MOH. However, our sample was subject to responder
bias due to the collection method employed and conse-
quently we are unable to assume that the results reflect
those of the general population, in fact, it is likely that
knowledge of MOH may have been overestimated in our
relatively educated cohort of responders. Thus, the is-
sues of lack of awareness of MOH may be a larger issue
than is highlighted in this small study. However, the use
of closed questions and multiple-choice responses could
have led to an overestimation in identifying awareness of
MOH. Analgesic use may be underestimated since our
study population was skewed towards the young and con-
sequently less likely to use analgesia owing to a decreased
occurrence of co-morbidities in this group. The pragmatic
approach to the study meant that healthcare training,
headache characteristics and medication intake were self-
reported and not formally verified. The use of an online-
based questionnaire was a cost effective way to recruit a
relatively large sample size. A further strength was in thespeed with which responses could be gathered and ana-
lysed. The use of social networking sites in the distribution
of these questionnaires may be a useful tool for future re-
search, particularly if deployed though hospital trust social
media and twitter feeds. However, the responses reflect
the views of those willing to complete the questionnaire
and may not accurately represent the general population.
Our methodology also meant that it was not possible to
calculate uptake rates.
Our study identifies the need to carry out a long-term
study evaluating the efficacy of a preventative strategy to
reduce MOH. Furthermore, the conversion of predicted to
actual changes in behaviour need evaluating. In summary,
there is a lack of awareness of MOH and our figures likely
underestimate the issue. Information regarding MOH may
alter behaviour and interventions, such as altering the
packaging of medications, may help reduce morbidity
from MOH. Finally, our responders indicated that chan-
ging the name of MOH to pain-killer induced headaches
would be preferable.Additional files
Additional file 1: Table S1. Questions issued to participants to
complete.
Additional file 2: Figure S1. Medication usage between the two
groups demonstrates no significant changes apart from the use of aspirin.
Respondents consisted of healthcare educated (n = 197; grey bars) and
non-healthcare educated (n = 288; white bars) individuals. Data are
demonstrated as percentage of sample selected with the absolute
value below each bar. *Indicates p < 0.05.Competing interests
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